A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS
Status:
Completed
Trial end date:
1992-06-01
Target enrollment:
Participant gender:
Summary
To test the effectiveness of itraconazole in preventing the recurrence of disseminated
histoplasmosis in AIDS patients.
Histoplasmosis is a serious opportunistic infection in patients with AIDS. Amphotericin B has
been used to treat the infection. Although the response to this treatment is generally good,
up to 90 percent of AIDS patients who have taken amphotericin B to treat their histoplasmosis
infection will have a relapse (that is, they will get the disease again) within 12 months
following treatment. Ketoconazole has been used to prevent relapse, but available information
suggests that up to 50 percent of AIDS patients relapse even with ketoconazole treatment. A
more effective therapy to prevent recurrence is needed. Itraconazole has been used
successfully to treat disseminated histoplasmosis in non-AIDS patients and it is hoped that
it may be more effective in preventing histoplasmosis relapse.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)